Advice
Indication withdrawn
The third-line treatment indication for rucaparib (Rubraca) has been withdrawn – see link
Medicine details
- Medicine name:
- rucaparib (Rubraca)
- SMC ID:
- SMC2221
- Indication:
As monotherapy treatment of adult patients with platinum sensitive, relapsed or progressive, BRCA mutated (germline and/or somatic), high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer, who have been treated with two or more prior lines of platinum based chemotherapy, and who are unable to tolerate further platinum based chemotherapy.
- Pharmaceutical company
- Clovis Oncology UK Limited
- BNF chapter
- Malignant disease and immunosuppression
- Submission type
- Non submission
- Status
- Withdrawn
- Date advice published
- 12 August 2019
Additional notes
The third-line treatment indication for rucaparib (Rubraca) has been withdrawn – see link
In line with SMC process the SMC advice has been removed from the website.